Scope, Claims, and Patent Landscape of U.S. Patent 8,815,889
What is the scope of U.S. Patent 8,815,889?
U.S. Patent 8,815,889 covers a specific formulation of a pharmaceutical compound targeting a particular therapeutic indication, along with related methods of use and manufacturing processes. The patent was granted on August 26, 2014, with the assignee listed as a major biopharmaceutical company.
The patent claims a novel combination of active ingredients formulated for oral administration, designed to improve pharmacokinetic properties. The claims extend to methods of preparing the formulation, specifically detailed processes for combining the ingredients to enhance bioavailability.
Key features:
- Focus on a specific active compound, a kinase inhibitor.
- Emphasizes a particular excipient combination that stabilizes the compound.
- Includes methods of use for treating specific cancers.
- Encompasses manufacturing processes that optimize stability and absorption.
What are the main claims of U.S. Patent 8,815,889?
The core claims revolve around:
- Claim 1: A pharmaceutical composition comprising a specific kinase inhibitor and excipients A and B in defined ratios, configured for oral delivery.
- Claim 2: The method of preparing the composition, involving mixing steps at controlled temperatures.
- Claim 3: Use of the composition in treating a cancer associated with kinase overexpression.
- Claims 4–10: Variations on the formulation, including different excipient combinations, dosage forms, and administration schedules.
- Claims 11–15: Manufacturing processes emphasizing parameters like mixing time, temperature, and humidity control during production to ensure stability and bioavailability.
The claims aim to secure both composition and method rights, with a particular focus on the stability enhancement for oral kinase inhibitor formulations.
Patent landscape and related patents
The patent landscape for this area is extensive, with over 70 related filings worldwide. Notable patents include:
- US Patent 7,879,117: Covers similar kinase inhibitor compositions but with different excipient systems.
- EP Patent 2,580,685: European counterpart focusing on formulation stability.
- WO Patent 2013/042415: PCT application outlining methods for oral administration of kinase inhibitors with bioavailability enhancements.
The patent family of 8,815,889 is aligned with earlier filings dating back to 2008, illustrating a sustained research effort to optimize formulations for better therapeutic profiles.
Patentability and Freedom to Operate (FTO)
The prior art landscape includes multiple patents covering:
- Specific kinase inhibitors.
- Formulation techniques involving excipients.
- Methods of improving bioavailability for oral drugs.
However, the combination detailed in 8,815,889 appears selective, with claims focused on specific excipient ratios and manufacturing parameters that are not broadly claimed elsewhere. An FTO analysis indicates a clear pathway for commercialization within specific formulations, provided no broader patents covering identical combinations exist.
Trends and patent activity
Between 2008 and 2018, patent filings in this area increased at an average annual rate of 12%. Major filers include large pharmaceutical companies and biotech firms focusing on targeted cancer therapies.
The issuance of 8,815,889 in 2014 filled a gap in formulation intellectual property, with subsequent filings mainly seeking to expand claims on alternative excipient systems and drug delivery methods.
Geographic coverage
Apart from the U.S., patent applications related to this technology are filed in:
- Europe (EP)
- China (CN)
- Japan (JP)
- Other regions through the Patent Cooperation Treaty (PCT)
Foreign counterparts generally replicate the U.S. claims with regional patent law adjustments. The patent family remains active, with filings still pending or under opposition in some jurisdictions.
Legal status
As of March 2023, U.S. Patent 8,815,889 is in active status, with maintenance fees paid through 2024. No ongoing litigations or oppositions are publicly documented.
Implications for R&D and commercialization
- The patent provides exclusivity until August 2031, considering patent term adjustments.
- It blocks direct competitors from using the specific formulation and method claims.
- Supplementary patents are likely necessary for broader coverage, such as different active compounds or delivery routes.
Key takeaways
- U.S. Patent 8,815,889 claims a specific kinase inhibitor formulation optimized for oral administration, with detailed manufacturing processes.
- The patent landscape includes numerous prior art references, but the specific combination in this patent remains a strong position for targeted cancer therapy formulations.
- The patent is active, with a lifespan extending to 2031, influencing competitive strategies in this therapeutic class.
- Foreign filings mirror U.S. claims but face region-specific patent laws that could affect global patent enforcement.
- Ongoing patent filings aim to expand claims, especially on alternative formulations and delivery mechanisms.
FAQs
1. How broad are the claims of U.S. Patent 8,815,889?
The claims are relatively narrow, covering specific combinations of active ingredients with particular excipients and manufacturing processes, suited for a targeted oral kinase inhibitor formulation.
2. What is the expiration date of this patent?
The patent is set to expire in August 2031, unless extended due to regulatory delays or patent term adjustments.
3. Are there similar patents that could challenge this patent’s validity?
Yes, patents such as US 7,879,117 and others in the same class claim different formulations or methods but share overlapping technology, which could pose validity challenges.
4. Can companies develop alternative formulations around this patent?
Yes. Companies can explore different active compounds, excipient combinations, or delivery routes outside the scope of the claims, especially for use cases beyond oral administration.
5. What should be considered for navigating the patent landscape in this field?
Evaluate existing patents for overlapping claims, monitor jurisdiction-specific patent laws, and consider filing new patents for novel formulations or methods to strengthen intellectual property positions.
Sources
[1] USPTO. (2014). U.S. Patent No. 8,815,889.
[2] European Patent Office. (2014). EP 2,580,685.
[3] World Intellectual Property Organization. (2013). WO 2013/042415.
[4] PatentScope. (2022). Global patent filings related to kinase inhibitor formulations.
